- Home
- LBTYA vs AKRO Comparison
LBTYA vs AKRO Comparison
Compare LBTYA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYA
- AKRO
- Stock Information
- Founded
- LBTYA 2004
- AKRO 2017
- Country
- LBTYA Bermuda
- AKRO United States
- Employees
- LBTYA N/A
- AKRO N/A
- Industry
- LBTYA Cable & Other Pay Television Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- LBTYA Telecommunications
- AKRO Health Care
- Exchange
- LBTYA Nasdaq
- AKRO Nasdaq
- Market Cap
- LBTYA 3.8B
- AKRO 3.7B
- IPO Year
- LBTYA N/A
- AKRO 2019
- Fundamental
- Price
- LBTYA $10.91
- AKRO $54.19
- Analyst Decision
- LBTYA Buy
- AKRO Buy
- Analyst Count
- LBTYA 5
- AKRO 10
- Target Price
- LBTYA $14.96
- AKRO $73.56
- AVG Volume (30 Days)
- LBTYA 2.2M
- AKRO 1.8M
- Earning Date
- LBTYA 10-30-2025
- AKRO 11-07-2025
- Dividend Yield
- LBTYA N/A
- AKRO N/A
- EPS Growth
- LBTYA N/A
- AKRO N/A
- EPS
- LBTYA N/A
- AKRO N/A
- Revenue
- LBTYA $4,770,600,000.00
- AKRO N/A
- Revenue This Year
- LBTYA $13.20
- AKRO N/A
- Revenue Next Year
- LBTYA $1.75
- AKRO N/A
- P/E Ratio
- LBTYA N/A
- AKRO N/A
- Revenue Growth
- LBTYA 170.50
- AKRO N/A
- 52 Week Low
- LBTYA $9.03
- AKRO $21.34
- 52 Week High
- LBTYA $14.30
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- LBTYA 48.70
- AKRO 68.59
- Support Level
- LBTYA $10.57
- AKRO $53.90
- Resistance Level
- LBTYA $11.01
- AKRO $54.31
- Average True Range (ATR)
- LBTYA 0.37
- AKRO 0.20
- MACD
- LBTYA 0.01
- AKRO -0.25
- Stochastic Oscillator
- LBTYA 57.22
- AKRO 83.45
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.